Pasi A. Jänne

125.6k total citations · 33 hit papers
653 papers, 61.5k citations indexed

About

Pasi A. Jänne is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Pasi A. Jänne has authored 653 papers receiving a total of 61.5k indexed citations (citations by other indexed papers that have themselves been cited), including 538 papers in Pulmonary and Respiratory Medicine, 429 papers in Oncology and 176 papers in Molecular Biology. Recurrent topics in Pasi A. Jänne's work include Lung Cancer Treatments and Mutations (487 papers), Colorectal Cancer Treatments and Studies (158 papers) and Lung Cancer Research Studies (142 papers). Pasi A. Jänne is often cited by papers focused on Lung Cancer Treatments and Mutations (487 papers), Colorectal Cancer Treatments and Studies (158 papers) and Lung Cancer Research Studies (142 papers). Pasi A. Jänne collaborates with scholars based in United States, Japan and South Korea. Pasi A. Jänne's co-authors include Bruce E. Johnson, Matthew Meyerson, Jeffrey A. Engelman, Michael J. Eck, Neal I. Lindeman, Titus J. Boggon, Geoffrey R. Oxnard, William R. Sellers, Heidi Greulich and Sean Tracy and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Pasi A. Jänne

628 papers receiving 60.2k citations

Hit Papers

EGFR Mutations in Lung Cancer: Correlation with Clinical ... 2004 2026 2011 2018 2004 2007 2005 2015 2005 2.5k 5.0k 7.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
    2004 7.5k citations J. Guillermo Paez, Pasi A. Jänne et al. profile →
  2. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
    2007 3.6k citations Jeffrey A. Engelman, Kreshnik Zejnullahu et al. profile →
  3. EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
    2005 3.2k citations Pasi A. Jänne, Matthew Meyerson et al. profile →
  4. AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
    2015 1.6k citations Pasi A. Jänne et al. profile →
  5. Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
    2005 1.2k citations Bruce E. Johnson, Pasi A. Jänne et al. Journal of Clinical Oncology profile →
  6. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
    2015 1.2k citations Cloud P. Paweletz, Yanan Kuang et al. profile →
  7. The quest to overcome resistance to EGFR-targeted therapies in cancer
    2013 819 citations Pasi A. Jänne et al. profile →
  8. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
    2009 785 citations Liang Chen, Marzia Capelletti et al. profile →
  9. Kinase drug discovery 20 years after imatinib: progress and future directions
    2021 670 citations Pasi A. Jänne et al. profile →
  10. First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
    2008 661 citations Lecia V. Sequist, Pasi A. Jänne et al. Journal of Clinical Oncology profile →
  11. Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
    2009 644 citations David M. Jackman, Jeffrey A. Engelman et al. Journal of Clinical Oncology profile →
  12. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
    2016 641 citations Geoffrey R. Oxnard, Ryan S. Alden et al. Journal of Clinical Oncology profile →
  13. Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor
    2010 604 citations James E. Butrynski, Marzia Capelletti et al. profile →
  14. PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
    2007 598 citations Jeffrey A. Engelman, Kreshnik Zejnullahu et al. Cancer Research profile →
  15. Noninvasive Detection of Response and Resistance in EGFR -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
    2014 590 citations Geoffrey R. Oxnard, Cloud P. Paweletz et al. Clinical Cancer Research profile →
  16. Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
    2008 559 citations Jeffrey A. Engelman, Pasi A. Jänne Clinical Cancer Research profile →
  17. Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants
    2005 536 citations Pasi A. Jänne, William R. Sellers et al. profile →
  18. Unique Clinicopathologic Features Characterize ALK -Rearranged Lung Adenocarcinoma in the Western Population
    2009 526 citations Scott J. Rodig, Mari Mino–Kenudson et al. Clinical Cancer Research profile →
  19. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
    2016 523 citations Pasi A. Jänne et al. Clinical Cancer Research profile →
  20. Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
    2018 513 citations Geoffrey R. Oxnard, Daniel B. Costa et al. profile →
  21. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
    2012 512 citations Pasi A. Jänne, Alice T. Shaw et al. profile →
  22. MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
    2016 493 citations Geoffrey R. Oxnard, David M. Jackman et al. Journal of Clinical Oncology profile →
  23. Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer
    2016 432 citations Adrian G. Sacher, Cloud P. Paweletz et al. profile →
  24. Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
    2017 380 citations Pasi A. Jänne et al. Journal of Clinical Oncology profile →
  25. Overcoming therapy resistance in EGFR-mutant lung cancer
    2021 338 citations Pasi A. Jänne et al. profile →
  26. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
    2020 248 citations Junji Tsurutani, Hiroji Iwata et al. Cancer Discovery profile →
  27. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)
    2022 206 citations Pasi A. Jänne, James G. Christensen et al. Journal of Clinical Oncology profile →
  28. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer
    2021 196 citations Pasi A. Jänne et al. profile →
  29. New promises and challenges in the treatment of advanced non-small-cell lung cancer
    2024 116 citations Federico Cappuzzo, Pasi A. Jänne et al. profile →
  30. Lung cancer in patients who have never smoked — an emerging disease
    2024 102 citations David C. Christiani, Pasi A. Jänne et al. profile →
  31. Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON
    2022 95 citations Lecia V. Sequist, Pasi A. Jänne et al. Cancer Discovery profile →
  32. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
    2024 76 citations Kazuhiko Nakagawa, Bob T. Li et al. profile →
  33. Transferrin receptor targeting chimeras for membrane protein degradation
    2024 59 citations Pasi A. Jänne et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pasi A. Jänne United States 115 40.7k 35.9k 25.7k 13.6k 4.9k 653 61.5k
Vincent A. Miller United States 92 30.6k 0.8× 29.8k 0.8× 16.1k 0.6× 10.5k 0.8× 4.3k 0.9× 478 45.7k
James Chih‐Hsin Yang Taiwan 107 33.9k 0.8× 46.1k 1.3× 18.4k 0.7× 9.4k 0.7× 2.6k 0.5× 698 66.2k
Tony Mok Hong Kong 98 39.6k 1.0× 35.7k 1.0× 15.8k 0.6× 12.5k 0.9× 3.8k 0.8× 683 56.7k
Bruce E. Johnson United States 95 29.3k 0.7× 29.7k 0.8× 20.8k 0.8× 9.7k 0.7× 3.9k 0.8× 420 50.6k
Roy S. Herbst United States 102 26.5k 0.7× 31.9k 0.9× 17.0k 0.7× 9.2k 0.7× 2.5k 0.5× 583 50.9k
William Pao United States 86 24.1k 0.6× 21.0k 0.6× 14.2k 0.6× 8.0k 0.6× 2.5k 0.5× 230 35.5k
Johann S. de Bono United Kingdom 108 29.0k 0.7× 22.3k 0.6× 18.9k 0.7× 14.1k 1.0× 2.3k 0.5× 1.0k 53.2k
José Baselga United States 98 14.1k 0.3× 25.8k 0.7× 19.7k 0.8× 9.8k 0.7× 3.3k 0.7× 484 46.7k
Tetsuya Mitsudomi Japan 92 22.7k 0.6× 18.1k 0.5× 14.6k 0.6× 8.5k 0.6× 2.5k 0.5× 529 36.6k
Jeffrey A. Engelman United States 91 13.8k 0.3× 16.0k 0.4× 21.3k 0.8× 6.2k 0.5× 3.6k 0.7× 187 36.0k

Countries citing papers authored by Pasi A. Jänne

Since Specialization
Citations

This map shows the geographic impact of Pasi A. Jänne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pasi A. Jänne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pasi A. Jänne more than expected).

Fields of papers citing papers by Pasi A. Jänne

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pasi A. Jänne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pasi A. Jänne. The network helps show where Pasi A. Jänne may publish in the future.

Co-authorship network of co-authors of Pasi A. Jänne

This figure shows the co-authorship network connecting the top 25 collaborators of Pasi A. Jänne. A scholar is included among the top collaborators of Pasi A. Jänne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pasi A. Jänne. Pasi A. Jänne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Beyett, Tyler S., Ciric To, David E. Heppner, et al.. (2022). Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors. Nature Communications. 13(1). 2530–2530. 56 indexed citations
2.
Tsurutani, Junji, Hiroji Iwata, Ian E. Krop, et al.. (2020). Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Cancer Discovery. 10(5). 688–701. 248 indexed citations breakdown →
3.
Jang, Jaebong, Jieun Son, Eunyoung Park, et al.. (2018). Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor. Angewandte Chemie International Edition. 57(36). 11629–11633. 23 indexed citations
4.
Koga, T., Yoshihisa Kobayashi, Kenji Tomizawa, et al.. (2018). Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study. Lung Cancer. 126. 72–79. 52 indexed citations
5.
Redig, Amanda J., Marzia Capelletti, Suzanne E. Dahlberg, et al.. (2016). Clinical and Molecular Characteristics of NF1 -Mutant Lung Cancer. Clinical Cancer Research. 22(13). 3148–3156. 53 indexed citations
6.
Yanagita, Masahiko, Amanda J. Redig, Cloud P. Paweletz, et al.. (2016). A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. Clinical Cancer Research. 22(24). 6010–6020. 92 indexed citations
7.
Paweletz, Cloud P., Adrian G. Sacher, Ryan S. Alden, et al.. (2015). Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients. Clinical Cancer Research. 22(4). 915–922. 177 indexed citations
8.
Soucheray, Margaret, Marzia Capelletti, Yanan Kuang, et al.. (2015). Intratumoral Heterogeneity in EGFR -Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. Cancer Research. 75(20). 4372–4383. 103 indexed citations
9.
Cardarella, Stephanie, Atsuko Ogino, Mizuki Nishino, et al.. (2013). Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer. Clinical Cancer Research. 19(16). 4532–4540. 274 indexed citations
10.
Chen, Zhao, Esra A. Akbay, Oliver R. Mikse, et al.. (2013). Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK -Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance. Clinical Cancer Research. 20(5). 1204–1211. 51 indexed citations
11.
Yuen, Hiu‐Fung, James T. Murray, Angela Platt‐Higgins, et al.. (2011). Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways. Clinical Cancer Research. 18(2). 380–391. 4 indexed citations
12.
Takezawa, Ken, Isamu Okamoto, Kazuto Nishio, Pasi A. Jänne, & Kazuhiko Nakagawa. (2011). Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer. Clinical Cancer Research. 17(8). 2140–2148. 115 indexed citations
13.
Sasaki, Takaaki, Katsuhiro Okuda, Wei Zheng, et al.. (2010). The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers. Cancer Research. 70(24). 10038–10043. 254 indexed citations
14.
Rodig, Scott J., Mari Mino–Kenudson, Sanja Đačić, et al.. (2009). Unique Clinicopathologic Features Characterize ALK -Rearranged Lung Adenocarcinoma in the Western Population. Clinical Cancer Research. 15(16). 5216–5223. 526 indexed citations breakdown →
15.
Yonesaka, Kimio, Kreshnik Zejnullahu, Neal I. Lindeman, et al.. (2008). Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers. Clinical Cancer Research. 14(21). 6963–6973. 96 indexed citations
16.
17.
Engelman, Jeffrey A., Kreshnik Zejnullahu, Eugene Lifshits, et al.. (2007). PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib. Cancer Research. 67(24). 11924–11932. 598 indexed citations breakdown →
18.
Jackman, David M., Beow Y. Yeap, Lecia V. Sequist, et al.. (2006). Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib. Clinical Cancer Research. 12(13). 3908–3914. 491 indexed citations
19.
Zhao, Xiaojun, Barbara A. Weir, Thomas LaFramboise, et al.. (2005). Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis. Cancer Research. 65(13). 5561–5570. 242 indexed citations
20.
Zhao, Xiaojun, Cheng Li, J. Guillermo Paez, et al.. (2004). An Integrated View of Copy Number and Allelic Alterations in the Cancer Genome Using Single Nucleotide Polymorphism Arrays. Cancer Research. 64(9). 3060–3071. 401 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vincent A. Miller Breakdown of academic impact, for papers by James Chih‐Hsin Yang Breakdown of academic impact, for papers by Tony Mok Breakdown of academic impact, for papers by Bruce E. Johnson Breakdown of academic impact, for papers by Roy S. Herbst Breakdown of academic impact, for papers by William Pao Breakdown of academic impact, for papers by Johann S. de Bono Breakdown of academic impact, for papers by José Baselga Breakdown of academic impact, for papers by Tetsuya Mitsudomi Breakdown of academic impact, for papers by Jeffrey A. Engelman
Rankless by CCL
2026